Combination therapy, including adjuvant and neoadjuvant approaches, has become a cornerstone in lung cancer management, offering significant benefits before, during, and after primary treatment.
Nivolumab, alone or with Ipilimumab, is an FDA-approved immunotherapy option or combination to treat many types of non-small cell lung cancer (NSCLC). It is used: As first-line therapy with ipilimumab in adults whose cancer is metastatic and has the PD-L1 protein but does not have mutations in the EGFR or ALK gene. As first-line therapy […]
[…] fancied herself a poster child for early detection. And for many years, she was. An Ongoing Battle Against a Recurring Diagnosis After undergoing surgery then, as an adjuvant therapy, Jill spent 15 months on a targeted therapy for EGFR+. Despite the availability of a clinical trial, its location halfway across the country made it impossible […]
[…] the immune system attacking cancer cells. It's used for NSCLC that has: Spread to other parts of the body A protein called PD-L1 No changes in genes called EGFR or ALK Ipilimumab can be used: As a first treatment for some patients With other cancer drugs called chemotherapy Before surgery (neo- adjuvant) for early-stage NSCLC
[…] is ALK-positive and has metastasized (spread to other parts of the body). FDA approved alectinib (Alecensa) for people with non-small cell lung cancer (NSCLC) who have ALK-positive tumors that can be removed with surgery. Based on the ALINA trial results, the Food and Drug Administration (FDA) approved alectinib as adjuvant therapy for people with ALK-positive NSCLC.
